These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18610730)

  • 41. The FDA, preemption, and the Supreme Court.
    Glantz LH; Annas GJ
    N Engl J Med; 2008 May; 358(18):1883-5. PubMed ID: 18450601
    [No Abstract]   [Full Text] [Related]  

  • 42. Medical liability, product liability, and the question of tort reform.
    Ross-Lee B; Kiss L; Weiser MA
    J Am Osteopath Assoc; 1994 Dec; 94(12):1039-49. PubMed ID: 7852103
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prescription for fairness: a new approach to tort liability of brand-name and generic drug manufacturers.
    Rostron A
    Duke Law J; 2011 Feb; 60(5):1123-91. PubMed ID: 21365961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Introduction to the new prescription drug labeling by the Food and Drug Administration.
    Lal R; Kremzner M
    Am J Health Syst Pharm; 2007 Dec; 64(23):2488-94. PubMed ID: 18029957
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FDA approval of comparative claims for prescription drugs--the Moxam case.
    Marcus D
    Drug Inf J; 1983; 17(3):171-5. PubMed ID: 10265094
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Your business in court and at Federal agencies: 2011-2012.
    Reiss JB; Crowder D; McCabe B; DeFeo M; Rifin M; Talbot M
    Food Drug Law J; 2013; 68(1):1-51, i. PubMed ID: 24640636
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
    Boumil MM; Curfman G
    JAMA; 2018 Aug; 320(6):547-548. PubMed ID: 30039167
    [No Abstract]   [Full Text] [Related]  

  • 48. The impact of the recent Supreme Court rulings in Pegram and Rush Prudential on state regulation of managed care organizations.
    Trueman DL
    J Health Law; 2003; 36(1):107-32. PubMed ID: 12784923
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Law & psychiatry: SSRIs, suicide, and liability for failure to warn of medication risks.
    Appelbaum PS
    Psychiatr Serv; 2011 Apr; 62(4):347-9. PubMed ID: 21459983
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prescription drug product labeling; medication guide requirements--FDA. Final rule.
    Fed Regist; 1998 Dec; 63(230):66378-400. PubMed ID: 10338877
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Will the Supreme Court finally eliminate ERISA preemption?
    Trueman DL
    Ann Health Law; 2004; 13(2):427-64, table of contents. PubMed ID: 15281484
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tort reform--what about caps?
    Freeman J
    Iowa Med; 2003; 93(2):26. PubMed ID: 12728608
    [No Abstract]   [Full Text] [Related]  

  • 53. Discovery rule in medical malpractice under the Federal Tort Claims Act: the Supreme Court's decision in United States v. Kubrick was not meant to be secondary authority.
    Zajdel C
    J Contemp Health Law Policy; 2004; 20(2):443-66. PubMed ID: 15239365
    [No Abstract]   [Full Text] [Related]  

  • 54. The "natural" aversion: the FDA's reluctance to define a leading food-industry marketing claim, and the pressing need for a workable rule.
    Farris AL
    Food Drug Law J; 2010; 65(2):403-24, iv. PubMed ID: 24475548
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patient follow-up: the scope of the duty, the impact of tort law reform and practical suggestions to comply with legal requirements.
    Ellis M
    J Law Med; 2007 Dec; 15(3):408-22. PubMed ID: 18251424
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 57. Federal preemption of common law tort awards by the Federal Food, Drug, and Cosmetic Act.
    Carrier MK
    Food Drug Law J; 1996; 51(4):509-611. PubMed ID: 11797729
    [No Abstract]   [Full Text] [Related]  

  • 58. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
    Vladeck DC
    Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
    [No Abstract]   [Full Text] [Related]  

  • 59. Is it time to abandon FDA's no release from liability regulation for clinical studies?
    Winter JD
    Food Drug Law J; 2008; 63(2):525-36. PubMed ID: 18561476
    [No Abstract]   [Full Text] [Related]  

  • 60. Medical Malpractice and Tort Reform.
    White R;
    Issue Brief Health Policy Track Serv; 2017 Dec; 2017():1-20. PubMed ID: 29360294
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.